GP

Gary Phillips

Pharmaxis Ltd | Chief Executive Officer, Managing Director
Mr Phillips has more than 40 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia. After managing country operations for Novartis in Eastern Europe and Asia, Gary came to Australia as CEO of Novartis in 2001, successfully launching leading oncology and ophthalmology products. He joined Pharmaxis in December 2003 when the company listed on the Australian Securities Exchange. Following his appointment as Pharmaxis CEO in 2013, Gary has overseen a company restructure focused on building value, forging commercial partnerships and fostering the development of the Pharmaxis product pipeline. Pharmaxis has commercial partnerships in place with Pharma companies for drugs in asthma and cystic fibrosis and a pipeline with clinical stage assets in oncology, fibrosis and inflammation.

Companies and Roles

Company
Title
Tenure
Since
PXS
Pharmaxis Ltd
  • Chief Executive Officer
  • Managing Director
11yrs, 2mthMar 2013
SNT
Syntara Limited
  • Chief Executive Officer
  • Managing Director
11yrs, 2mthMar 2013
ALA
Arovella Therapeutics Limited
  • Non-Executive Director
1yrs, 10mthJul 2022

Holdings

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
ALA
Arovella Therapeutics Limited
28/03/240788,8882,128,000N/A
PXS
Pharmaxis Ltd
29/11/235,699,8435,369,1046,845,800N/A
SNT
Syntara Limited
29/11/235,699,8435,369,1046,845,800N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
ALA
Arovella Therapeutics Limited
28/03/24
Buy
66,666$0.150$10,000On-market trade
ALA
Arovella Therapeutics Limited
04/12/23
Issued
618,000$0.088$54,384Director remuneration
PXS
Pharmaxis Ltd
29/11/23
Issued
2,771,000$0.030$83,130Issue of options
SNT
Syntara Limited
29/11/23
Issued
2,771,000$0.030$83,130Issue of options
ALA
Arovella Therapeutics Limited
12/07/23
Issued
222,222$0.045$9,999Participation in share purchase plan